Repligen Co. (NASDAQ:RGEN) Stake Lessened by HighTower Advisors LLC

HighTower Advisors LLC decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 13.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 5,234 shares of the biotechnology company’s stock after selling 788 shares during the quarter. HighTower Advisors LLC’s holdings in Repligen were worth $773,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of RGEN. Raymond James & Associates grew its stake in Repligen by 3.7% during the 2nd quarter. Raymond James & Associates now owns 55,119 shares of the biotechnology company’s stock valued at $6,948,000 after acquiring an additional 1,951 shares in the last quarter. Fifth Third Bancorp grew its position in Repligen by 6.4% during the second quarter. Fifth Third Bancorp now owns 3,096 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 187 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in Repligen in the 2nd quarter valued at approximately $273,000. Slow Capital Inc. lifted its position in Repligen by 10.7% in the 2nd quarter. Slow Capital Inc. now owns 16,165 shares of the biotechnology company’s stock worth $2,038,000 after buying an additional 1,558 shares in the last quarter. Finally, Banque Pictet & Cie SA boosted its stake in shares of Repligen by 74.6% during the 2nd quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock valued at $4,351,000 after buying an additional 14,746 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Price Performance

NASDAQ RGEN opened at $147.34 on Thursday. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a fifty day simple moving average of $143.61 and a 200 day simple moving average of $141.74. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.26 billion, a P/E ratio of -398.21, a P/E/G ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the company earned $0.23 earnings per share. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, sell-side analysts predict that Repligen Co. will post 1.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on RGEN shares. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Wells Fargo & Company started coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target for the company. Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday. They issued a “hold” rating and a $165.00 price target for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $185.20.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.